AU6986201A
(en)
|
2000-06-16 |
2002-01-02 |
Biogen Inc |
Renal regulatory elements and methods of use thereof
|
US20060035237A1
(en)
|
2002-08-26 |
2006-02-16 |
Markowitz Sanford D |
Methods and compositions for categorizing patients
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
ATE382060T1
(de)
|
2001-06-01 |
2008-01-15 |
Biogen Idec Inc |
Moleküle und verfahren zur inhibierung der freisetzung von kim-1
|
AU2002330713A1
(en)
*
|
2001-09-24 |
2003-04-07 |
University Of Aarhus |
Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ATE364690T1
(de)
|
2001-11-09 |
2007-07-15 |
Proteologics Inc |
Posh nukleinsäure, polypeptide und darauf bezogene verfahren
|
CA2479732A1
(en)
*
|
2002-03-19 |
2003-10-02 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
WO2003087408A2
(en)
*
|
2002-04-05 |
2003-10-23 |
University Court Of The University Of Edinburgh |
Schizophrenia associated genes
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
WO2004001060A2
(en)
|
2002-06-20 |
2003-12-31 |
Bristol-Myers Squibb Company |
Identification and regulation of a g-protein coupled receptor, rai-3
|
GB0215224D0
(en)
*
|
2002-07-01 |
2002-08-14 |
Inpharmatica Ltd |
Protein
|
EP1578762A4
(de)
*
|
2002-11-12 |
2006-08-02 |
Wyeth Corp |
Neues, auf pthansprechendes gen
|
CN1835769B
(zh)
|
2002-12-30 |
2011-06-29 |
比奥根艾迪克Ma公司 |
Kim-1拮抗剂及其在免疫系统调节中的应用
|
JP4462964B2
(ja)
*
|
2003-03-10 |
2010-05-12 |
第一三共株式会社 |
癌特異的抗原を標的とした抗体
|
EP1615991A4
(de)
|
2003-04-03 |
2007-12-19 |
Bristol Myers Squibb Co |
Neue menschliche p2x7-spleissvariante hbmyp2x7v codierendes polynukleotid
|
EP1923401A3
(de)
*
|
2003-04-14 |
2008-08-20 |
Novartis AG |
Genexpression in Zusammenhang mit Osteoblastendifferenzierung
|
EP1623230A2
(de)
*
|
2003-05-05 |
2006-02-08 |
Bayer HealthCare AG |
Diagnostika und therapeutika für krankheiten, die mit gpr39 (g-protein coupled receptor gpr39) assoziiert sind
|
WO2005001049A2
(en)
*
|
2003-06-06 |
2005-01-06 |
Diadexus, Inc. |
Compositions, splice variants and methods relating to ovarian specific genes and proteins
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
WO2005066363A2
(en)
*
|
2004-01-09 |
2005-07-21 |
Medigen Biotechnology Corporation |
Cancer specific gene ccndbp1
|
US20050186577A1
(en)
|
2004-02-20 |
2005-08-25 |
Yixin Wang |
Breast cancer prognostics
|
GB0404209D0
(en)
*
|
2004-02-25 |
2004-03-31 |
Uws Ventures Ltd |
Materials and methods for treatment of allergic disease
|
EP1721165B1
(de)
*
|
2004-02-27 |
2010-03-03 |
Institut Curie |
Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
|
US8124730B1
(en)
|
2004-04-02 |
2012-02-28 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
|
EP1741792B1
(de)
|
2004-04-27 |
2010-11-03 |
Takeda Pharmaceutical Company Limited |
Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
|
EP1747467A1
(de)
*
|
2004-05-11 |
2007-01-31 |
Bayer HealthCare AG |
Diagnostika und therapeutika für mit dipeptidyl-peptidase 6 (dpp6) assoziierten krankheiten
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
ZA200701183B
(en)
|
2004-07-20 |
2008-05-28 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein, combinations, an their use
|
ZA200701184B
(en)
|
2004-07-20 |
2008-07-30 |
Genentech Inc |
Compositions and methods of using angiopoietin-like 4 protein
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CA2599967C
(en)
|
2005-03-02 |
2014-10-21 |
Biogen Idec Ma Inc. |
Kim-1 antibodies for treatment of th2-mediated conditions
|
EP1871797A2
(de)
*
|
2005-04-18 |
2008-01-02 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Toll-like receptor 14 (tlr 14) und anwendung davon
|
WO2007008647A2
(en)
*
|
2005-07-07 |
2007-01-18 |
Vanderbilt University |
Diagnosing and grading gliomas using a proteomics approach
|
CN101415325A
(zh)
*
|
2005-11-29 |
2009-04-22 |
内华达肿瘤研究所 |
用于治疗和诊断与骨髓增生异常综合征(mds)相关的增殖性病症的sall4的靶向
|
AU2006321841C1
(en)
|
2005-12-08 |
2013-01-24 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
|
AR059432A1
(es)
|
2006-02-10 |
2008-04-09 |
Genentech Inc |
Anticuerpos anti-fgf19 y metodos que usan estos
|
NZ571068A
(en)
|
2006-03-21 |
2012-06-29 |
Genentech Inc |
An antibody that can bind human alpha5beta1
|
US7723052B2
(en)
|
2006-05-11 |
2010-05-25 |
Quark Pharmaceuticals, Inc. |
Screening systems utilizing RTP801
|
WO2007141796A2
(en)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of rtp801l
|
US7851144B2
(en)
|
2006-08-18 |
2010-12-14 |
The University Of Washington |
Compositions and methods for detecting cancer
|
GB0620695D0
(en)
*
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Composition and methods for the treatment of nurdegenerative disease
|
GB0620705D0
(en)
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
|
EP1932854A1
(de)
*
|
2006-12-15 |
2008-06-18 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Lysosomal assoziiertes Membranprotein (LAMP) wie Polypeptide, Liganden dazu und Verwendung davon im Rahmen der Detektion und Reinigung menschlicher, plasmazytoider dendritischer Zellen
|
EP2377952A1
(de)
*
|
2007-04-26 |
2011-10-19 |
Ludwig Institute For Cancer Research |
Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
|
DK2567707T3
(en)
*
|
2007-07-27 |
2017-07-31 |
Immatics Biotechnologies Gmbh |
Composition of tumour-associated peptides and related anti-cancer vaccine
|
CA2693852C
(en)
|
2007-08-03 |
2016-11-29 |
Genentech, Inc. |
Humanized anti-fgf19 antagonists and methods using same
|
CA2736170A1
(en)
|
2007-09-06 |
2009-03-12 |
Case Western Reserve University |
Methods for diagnosing and treating cancers
|
CL2008002856A1
(es)
|
2007-09-26 |
2009-01-16 |
Genentech Inc |
Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
WO2010002862A2
(en)
|
2008-07-01 |
2010-01-07 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (fgfr3) binding proteins
|
CN102159248B
(zh)
|
2008-07-15 |
2013-09-11 |
健泰科生物技术公司 |
蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
|
EP2326731B1
(de)
*
|
2008-08-25 |
2013-11-13 |
Janssen Biotech, Inc. |
Biomarker zur anti-tnf-behandlung bei colitis ulcerosa und damit zusammenhängenden erkrankungen
|
WO2010047310A1
(ja)
|
2008-10-20 |
2010-04-29 |
大日本住友製薬株式会社 |
腫瘍抗原ペプチド及びその利用
|
AU2014201027B2
(en)
*
|
2008-12-08 |
2015-11-19 |
Compugen Ltd. |
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
CA2745492A1
(en)
|
2008-12-08 |
2010-06-17 |
Compugen Ltd. |
A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗-α5β1抗體及其用途
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
HRP20211444T1
(hr)
|
2010-01-29 |
2021-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dll3 antitijelo
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
EP2662095A1
(de)
|
2010-04-15 |
2013-11-13 |
Spirogen Sàrl |
Pyrrolobenzodiazepine und Konjugate daraus
|
RU2755066C2
(ru)
|
2010-06-08 |
2021-09-13 |
Дженентек, Инк. |
Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
|
US20120121615A1
(en)
|
2010-11-17 |
2012-05-17 |
Flygare John A |
Alaninyl maytansinol antibody conjugates
|
US8679767B2
(en)
|
2011-05-12 |
2014-03-25 |
Genentech, Inc. |
Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
|
PT2750713E
(pt)
|
2011-10-14 |
2016-01-20 |
Genentech Inc |
Pirrolobenzodiazepinas e conjugados das mesmas
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
CN108530535B
(zh)
|
2012-02-15 |
2021-02-26 |
诺和诺德股份有限公司 |
结合肽聚糖识别蛋白1的抗体
|
ES2640268T3
(es)
|
2012-02-15 |
2017-11-02 |
Novo Nordisk A/S |
Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
RU2015106673A
(ru)
|
2012-08-02 |
2016-09-20 |
Дженентек, Инк. |
Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
|
WO2014022680A1
(en)
|
2012-08-02 |
2014-02-06 |
Genentech, Inc. |
Anti-etbr antibodies and immunoconjugates
|
EP2906253B9
(de)
|
2012-10-12 |
2019-04-10 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
|
ES2660029T3
(es)
|
2012-10-12 |
2018-03-20 |
Medimmune Limited |
Conjugados de anticuerpo-pirrolobenzodiazepinas
|
BR112015008174B1
(pt)
|
2012-10-12 |
2022-12-27 |
Medimmune Limited |
Conjugados de pirrolobenzodiazepina-anticorpo, composição farmacêutica compreendendo ditos conjugados e usos dos mesmos para tratar doença proliferativa e cancêr
|
NZ707490A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
CA2885340C
(en)
|
2012-10-12 |
2016-11-08 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
DK2906296T3
(en)
|
2012-10-12 |
2018-05-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
EP2906250B1
(de)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
BR112015014669B1
(pt)
|
2012-12-21 |
2023-09-26 |
Medimmune Limited |
Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
|
KR102066319B1
(ko)
|
2013-03-13 |
2020-01-14 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
CN105142674B
(zh)
|
2013-03-13 |
2018-11-13 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
CN105307685B
(zh)
|
2013-03-13 |
2019-03-08 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
WO2014159562A1
(en)
|
2013-03-14 |
2014-10-02 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
MX2016001862A
(es)
|
2013-08-12 |
2016-08-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
|
EP3054986B1
(de)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
MX2016007578A
(es)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
|
WO2015095227A2
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
EP3082874A2
(de)
|
2013-12-16 |
2016-10-26 |
Genentech, Inc. |
Peptidomimetische verbindungen und antikörper-wirkstoff-konjugate davon
|
FI3172232T3
(fi)
|
2014-07-17 |
2024-03-19 |
Novo Nordisk As |
TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP6622293B2
(ja)
|
2014-09-12 |
2019-12-18 |
ジェネンテック, インコーポレイテッド |
アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
WO2016044560A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
BR112017011111A2
(pt)
|
2014-11-25 |
2017-12-26 |
Adc Therapeutics Sa |
conjugados de pirrolobenzodiazepina-anticorpo
|
MX2017007169A
(es)
|
2014-12-03 |
2018-05-02 |
Genentech Inc |
Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017165734A1
(en)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017201449A1
(en)
|
2016-05-20 |
2017-11-23 |
Genentech, Inc. |
Protac antibody conjugates and methods of use
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2017214024A1
(en)
|
2016-06-06 |
2017-12-14 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
WO2018065501A1
(en)
|
2016-10-05 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Methods for preparing antibody drug conjugates
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
US11160872B2
(en)
|
2017-02-08 |
2021-11-02 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
DK3612537T3
(da)
|
2017-04-18 |
2022-08-08 |
Medimmune Ltd |
Pyrrolobenzodiazepinkonjugater
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
JP7145891B2
(ja)
|
2017-06-14 |
2022-10-03 |
アーデーセー セラピューティクス ソシエテ アノニム |
抗cd19 adcを投与するための投与レジメ
|
SG11202000358YA
(en)
|
2017-08-18 |
2020-02-27 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
JP2020534300A
(ja)
|
2017-09-20 |
2020-11-26 |
ピーエイチ・ファーマ・カンパニー・リミテッドPh Pharma Co., Ltd. |
タイランスタチン類似体
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
JOP20200240A1
(ar)
|
2018-04-02 |
2020-09-27 |
Bristol Myers Squibb Co |
أجسام مضادة ضد- trem-1 واستخداماتها
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3870235A1
(de)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Konjugierte chemische abbauauslöser und verwendungsverfahren
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
JP7085666B2
(ja)
|
2020-03-31 |
2022-06-16 |
中外製薬株式会社 |
Dll3標的多重特異性抗原結合分子およびその使用
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
CN114113603B
(zh)
*
|
2021-06-30 |
2023-11-17 |
四川大学华西医院 |
Cytl1作为胃癌预后标志物的应用
|